Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLLNASDAQ:ENTANASDAQ:IMGNNASDAQ:KURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$29.56+2.3%$28.12$23.23▼$42.29$949.82M0.63434,642 shs434,633 shsENTAEnanta Pharmaceuticals$5.55+5.3%$5.63$4.09▼$17.24$118.40M0.81284,961 shs106,054 shsIMGNImmunoGen$31.23$31.23$3.61▼$31.25$8.32B1.188.78 million shs40 shsKURAKura Oncology$6.09+5.7%$6.54$5.41▼$23.48$498.67M0.51.17 million shs936,096 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+2.32%+6.41%+12.40%-6.40%-6.16%ENTAEnanta Pharmaceuticals+5.31%+2.02%+18.34%-0.72%-56.13%IMGNImmunoGen0.00%0.00%0.00%0.00%0.00%KURAKura Oncology+5.55%-9.38%+5.55%-26.98%-70.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOLLCollegium Pharmaceutical4.032 of 5 stars3.41.00.03.02.60.82.5ENTAEnanta Pharmaceuticals3.8608 of 5 stars3.41.00.04.73.32.50.0IMGNImmunoGenN/AN/AN/AN/AN/AN/AN/AN/AKURAKura Oncology4.3689 of 5 stars4.52.00.04.73.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.80Moderate Buy$43.8048.17% UpsideENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25210.81% UpsideIMGNImmunoGen 0.00N/AN/AN/AKURAKura Oncology 2.92Moderate Buy$23.89292.26% UpsideCurrent Analyst Ratings BreakdownLatest COLL, KURA, ENTA, and IMGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.005/2/2025KURAKura OncologyBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $11.004/29/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.00 ➝ $28.004/28/2025KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.004/9/2025COLLCollegium PharmaceuticalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/8/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$36.003/24/2025COLLCollegium PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.003/6/2025KURAKura OncologyUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$27.00 ➝ $14.003/4/2025KURAKura OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/27/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$36.002/27/2025KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.50$10.71 per share2.76$5.99 per share4.93ENTAEnanta Pharmaceuticals$66.59M1.78N/AN/A$5.24 per share1.06IMGNImmunoGen$287.61M28.91N/AN/A$0.71 per share43.99KURAKura Oncology$67.99M7.75N/AN/A$5.35 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$48.15M$1.8612.744.91N/A14.78%104.67%18.38%N/AENTAEnanta Pharmaceuticals-$116.04M-$4.95N/AN/AN/A-157.57%-75.53%-27.30%N/AIMGNImmunoGen-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/AKURAKura Oncology-$152.63M-$2.10N/AN/AN/AN/A-44.09%-39.57%N/ALatest COLL, KURA, ENTA, and IMGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/1/2025Q1 2025KURAKura Oncology-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million2/27/2025Q4 2024COLLCollegium Pharmaceutical$1.54$1.63+$0.09$0.36$179.68 million$181.95 million2/26/2025Q4 2024KURAKura Oncology-$0.65-$0.22+$0.43-$0.22$57.96 million$53.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AIMGNImmunoGenN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.430.970.88ENTAEnanta PharmaceuticalsN/A5.475.47IMGNImmunoGen0.135.705.65KURAKura Oncology0.0211.4711.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AENTAEnanta Pharmaceuticals94.99%IMGNImmunoGen90.50%KURAKura OncologyN/AInsider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%ENTAEnanta Pharmaceuticals13.89%IMGNImmunoGen5.07%KURAKura Oncology6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.13 million30.97 millionOptionableENTAEnanta Pharmaceuticals16021.33 million18.37 millionOptionableIMGNImmunoGen277266.26 million252.76 millionOptionableKURAKura Oncology13086.58 million73.49 millionOptionableCOLL, KURA, ENTA, and IMGN HeadlinesRecent News About These CompaniesKura Oncology, Inc. (NASDAQ:KURA) Holdings Reduced by Foresite Capital Management IV LLCMay 12 at 6:25 AM | marketbeat.comDimensional Fund Advisors LP Buys 372,196 Shares of Kura Oncology, Inc. (NASDAQ:KURA)May 12 at 3:18 AM | marketbeat.comKura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlookMay 7, 2025 | investing.comKura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by Algert Global LLCMay 7, 2025 | marketbeat.comKura Oncology, Inc. (NASDAQ:KURA) Receives $23.89 Average PT from AnalystsMay 7, 2025 | americanbankingnews.comBVF Inc. IL Sells 804,292 Shares of Kura Oncology, Inc. (NASDAQ:KURA)May 6, 2025 | marketbeat.comKura Oncology to Participate in Bank of America Securities Healthcare ConferenceMay 6, 2025 | globenewswire.comFY2026 EPS Estimates for Kura Oncology Increased by AnalystMay 6, 2025 | marketbeat.comFY2026 EPS Estimate for Kura Oncology Increased by AnalystMay 6, 2025 | americanbankingnews.comKura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of "Moderate Buy" by AnalystsMay 6, 2025 | marketbeat.comBarclays Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock PriceMay 5, 2025 | americanbankingnews.comKura Oncology (NASDAQ:KURA) Shares Gap Down on Disappointing EarningsMay 4, 2025 | marketbeat.comKura Oncology (NASDAQ:KURA) Price Target Lowered to $11.00 at BarclaysMay 4, 2025 | marketbeat.comScotiabank Keeps Their Hold Rating on Kura Oncology (KURA)May 4, 2025 | theglobeandmail.comBTIG Keeps Their Hold Rating on Kura Oncology (KURA)May 4, 2025 | theglobeandmail.comKura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by Aquatic Capital Management LLCMay 4, 2025 | marketbeat.comKura Oncology (NASDAQ:KURA) Downgraded by StockNews.com to "Hold"May 4, 2025 | americanbankingnews.comKura Oncology (NASDAQ:KURA) Shares Gap Down After Earnings MissMay 4, 2025 | americanbankingnews.comEarnings call transcript: Kura Oncology Q1 2025 reveals revenue boostMay 3, 2025 | investing.com4,451,041 Shares in Kura Oncology, Inc. (NASDAQ:KURA) Acquired by RA Capital Management L.P.May 3, 2025 | marketbeat.comQ1 2025 Kura Oncology Inc Earnings CallMay 2, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesFundamentally Sound, These 5 Stocks Sold Off AnywayBy Thomas Hughes | April 23, 2025View Fundamentally Sound, These 5 Stocks Sold Off Anyway3 Stocks Presenting Generational Buying OpportunitiesBy Chris Markoch | April 25, 2025View 3 Stocks Presenting Generational Buying Opportunities3 Stocks To Watch For When Tariffs Subside By Gabriel Osorio-Mazilli | April 25, 2025View 3 Stocks To Watch For When Tariffs Subside Occidental’s Hidden Gem: How OxyChem Could Boost ProfitsBy Jea Yu | April 29, 2025View Occidental’s Hidden Gem: How OxyChem Could Boost Profits3 Boring Stocks Outperforming the Market This YearBy Ryan Hasson | April 25, 2025View 3 Boring Stocks Outperforming the Market This YearCOLL, KURA, ENTA, and IMGN Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$29.56 +0.67 (+2.32%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$29.70 +0.14 (+0.47%) As of 04:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Enanta Pharmaceuticals NASDAQ:ENTA$5.55 +0.28 (+5.31%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$5.56 +0.02 (+0.27%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.ImmunoGen NASDAQ:IMGNImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.Kura Oncology NASDAQ:KURA$6.09 +0.33 (+5.73%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$6.31 +0.22 (+3.68%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
